

## DAFTAR PUSTAKA

1. Fitriatuzzakiyyah N, Sinuraya RK, Puspitasari IM. Terapi Kanker dengan Radiasi: Konsep Dasar Radioterapi dan Perkembangannya di Indonesia. *Jurnal Farmasi Klinik Indonesia*. 2017 Dec 1;6(4):311-20.
2. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit Kementerian Kesehatan RI. Riset kesehatan dasar (RISKESDAS) tahun 2019. <http://p2p.kemkes.go.id/penyakit-kanker-di-indonesia-berada-pada-urutan-8-di-asia-tenggara-dan-urutan-23-di-asia/>
3. Rasjidi I. Epidemiologi kanker serviks. *Indonesian Journal of cancer*. 2009 Oct 1;3(3).
4. Yulianti W. Asuhan Keperawatan Pada Ny. A 35 Tahun dengan Kanker Serviks Stadium IV+ Post Kemoterapi Cisplatin 2 Siklus di Rumah Sakit Umum Pusat Dr. Hasan Sadikin (Doctoral dissertation, Universitas Aisyiyah Bandung). 2021.
5. Silvia M. Hubungan Karakteristik Wanita Usia Subur dengan Hasil Pemeriksaan IVA di Wilayah Kerja Puskesmas Padang Pasir tahun 2017 (Doctoral dissertation, Universitas Andalas).
6. Yeni NY. Gambaran Faktor Risiko Kejadian Kanker Serviks di RSUP Dr. M. Djamil Padang (Doctoral dissertation, Universitas Andalas).2018.
7. Legianawati D, Puspitasari IM, Suwantika AA, Kusumadjadi A. Profil Penatalaksanaan Kanker Serviks Stadium IIB–IIIB dengan Terapi Radiasi dan Kemoradiasi di Rumah Sakit Umum Pusat Dr. Hasan Sadikin Bandung Periode Tahun 2015–2017. *Indonesian Journal of Clinical Pharmacy*. 2019 Sep 29;8(3):205-16.
8. Yuliati I, Perbowo P, Mulawardhana P, Nugroho H, Indraprasta BR, Harjanto B, Widhiarta KD, et al. *Panduan Tatalaksana Kanker Ginekologi*. Scopindo Media Pustaka; 2020 Jul 10.
9. Pribadi SY. Literature Review Analisa Efek Samping Kemoterapi pada Pasien Kanker Serviks di Asia (Doctoral dissertation, Universitas Muhammadiyah Magelang). 2021.
10. Widjanarko A. Peran Obat Herbal Dalam Pengobatan Kanker di Indonesia. *Indonesian Journal of Cancer*. 2010.
11. Latief, M., Tarigan, I.L., Sari, P.M. and Aurora, F.E. Aktivitas Antihiperurisemia Ekstrak Etanol Daun Sungkai (*Peronema canescens* Jack) Pada Mencit Putih Jantan. *Pharmacon: Jurnal Farmasi Indonesia*, 18(1). 2021:23-37.
12. Wilarso S. Silvikultur jenis Sungkai. Respository Institut Pertanian Bogor. <https://repository.ipb.ac.id/jspui/bitstream/123456789/65519/13/Silvikultur%20Jenis%20sungkai-Sri%20Wilarso%20Budi%20R.pdf>

13. Yani AP, Ruyani A, Yenita, Ansyori I, Irwanto R. Uji Potensi Daun Muda Sungkai (*Peronema canescens*) untuk Kesehatan (Imunitas) pada Mencit (*Mus. musculus*). *Jurnal Pendidikan Biologi FKIP Universitas Bengkulu*. 2017: 245-250.
14. Ibrahim, Arsyik, and Hadi Kuncoro. "Identifikasi metabolit sekunder dan aktivitas antibakteri ekstrak daun sungkai (*Peronema canescens* Jack.) terhadap beberapa bakteri patogen." *Journal of Tropical Pharmacy and Chemistry* 2.1.2012: 8-18.
15. Andespal, Sundaryono, Agus, Amir, Hermansyah. Profil Fitokimia Daun Sungkai (*Peronema canescens*) serta Uji Aktivitas Antioksidan dan Uji Sitotoksik Terhadap *Artemia Salina* Leach. Thesis, (Doctoral dissertation, Universitas Bengkulu). 2020.
16. Nawawi DS, Sari RK, Darmawan S. Eksplorasi Senyawa Antikanker dari Limbah Industri Kayu Rakyat. *Jurnal Institut Pertanian Bogor*. 2013.
17. Plantamor. Plantamor Situs Dunia Tumbuhan, Informasi Spesies-*Peronema canescens*. 2009. <http://plantamor.com/species/info/peronema/canescens>
18. Pratama, Ariyoga, Kasrina Kasrina, and Ariefa Primaryani. Pengembangan Lembar Kegiatan Siswa (LKS) Berdasarkan Riset Teratogenitas Morfologi Fetus Mencit (*Mus Musculus*) Swiss Webster Setelah Pemberian Ekstrak Daun Muda Sungkai (Doctoral Disertassion, Universitas Bengkulu). 2014.
19. Ilham, Pratama. Penentuan Kandungan Metabolit Sekunder, Uji Aktivitas Antibakteri dan Sitotoksik Ekstrak Daun Sungkai (*Peronema canescens* Jack). Diploma thesis, Universitas Andalas. 2021.
20. Fransisca, D., Kahanjak, D.N. and Frethernety, A. Uji aktivitas antibakteri ekstrak etanol daun sungkai (*Peronema canescens* Jack) terhadap pertumbuhan *Escherichia coli* dengan metode difusi cakram Kirby-Bauer. *Jurnal Pengelolaan Lingkungan Berkelanjutan*. 2020: 460-470.
21. Anisa, F. Karakterisasi dan Uji Aktivitas Antioksidan Terhadap Ekstrak Non Polar, Semi Polar, dan Polar dari Daun Sungkai (Doctoral Dissertation, Universitas Perintis Indonesia). 2021.
22. Panache AN, Diwan AD, Chandra SR. Flavonoids: an overview. *J Nutr Sci*. 2016.5:1-15.
23. Rodriguez GC, Sanchez QC, Gaforio JJ. Dietary flavonoids as cancer chemopreventive agents: an updated review of human studies. *Antioxidants (Basel)*. 2019;8(5):137.
24. Abotaleb M, Samuel SM, Varghese E, et al. Flavonoids in cancer and apoptosis. *Cancers (Basel)*. 2019;11(1):28.
25. Veeramuthu D, Raja WRT, Al-Dhabi NA, Savarimuthu I. Flavonoids: Anticancer Properties, From Biosynthesis to Human Health. 2017. <https://www.intechopen.com/chapters/56200>

26. Ramos S. Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. *The journal of Nutritional Biochemistry*. 2007;18:427-442.
27. Mondal A, Gandhi A, Fimognari C, Atanasov AG, Bishayee A. Alkaloids for cancer prevention and therapy: Current progress and future perspectives. *Eur J Pharmacol*. 2019.
28. Millimouno FM, Dong J, Li J, Li X. Targeting Apoptosis Pathways in Cancer and Perspectives With Natural Compounds From Mother Nature. *Cancer Prev Res (Phila)*. 2014;7(11):1081-107
29. Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. *Journal of Current Oncology*. 2009;16(2):36-43.
30. Basli A, Belkacem N, Amrani I. Phenolic Compounds: Biological Activity, Health Benefits of Phenolic Compounds Against Cancers. 2017. <https://www.intechopen.com/books/phenolic-compounds-biological-activity/health-benefits-of-phenolic-compounds-against-cancers>
31. Zujko ME, Witkowska AM. Antioxidant potential and polyphenol content of selected food. *International Journal of Food Properties*. 2011;14(2):300-308.
32. Zinoveva VN, Spasov AA. Mechanisms of plant polyphenol anti-cancer effects. I. Blockade of carcinogenesis initiation. *Biomeditsinskaja Khimiia*. 2012;58:160-175.
33. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. *Journal of Ethnopharmacology*. 2005;100:72-79.
34. Ansari IA, Akhtar MS. Current Insights on the Role of Terpenoids as Anticancer Agents: A Perspective on Cancer Prevention and Treatment. 2019. [https://doi.org/10.1007/978-981-13-7205-6\\_3](https://doi.org/10.1007/978-981-13-7205-6_3)
35. Polo MP, de Bravo MG. Effect of geraniol on fatty-acid and mevalonate metabolism in the human hepatoma cell line Hep G2. *Biochem Cell Biol*. 2006;84:102-111.
36. Abbas AK, Aster JC, Kumar V. *Buku Ajar Patologi Robbins*. Edisi 9. Singapura: Elsevier Saunders. 2015.
37. Kementerian Kesehatan RI. Pusat data dan informasi kesehatan: Bulan peduli kanker payudara. Kementerian Kesehatan RI. Jakarta. 2016.
38. Mayo Clinic. Diseases and Condition: Cervical Cancer. 2021. <https://www.mayoclinic.org/diseases-conditions/cervical-cancer/symptoms-causes/syc-20352501>
39. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *ACS Journals*, 2021;71(3):209-49.
40. KEMENKES RI. Panduan Penatalaksanaan Kanker Serviks. Jakarta: KEMENKES RI. 2014.

41. Wang X, Huang X, Zhang Y. Involvement of Human Papillomaviruses in Cervical Cancer. *Front Microbiol.* 2018;9:2896.
42. Manini I, Montomoli E. Epidemiology and prevention of Human Papillomavirus. *Ann Ig.* 2018;30:28-32.
43. Ghosh I, Mandal R, Kundu P, Biswas J. Association of Genital Infections Other Than Human Papillomavirus with Pre-Invasive and Invasive Cervical Neoplasia. *J Clin Diagn Res.* 2016;10(2):XE01-XE06.
44. Stark, Holger & Zivkovic, Aleksandra. HPV Vaccination: Prevention of Cervical Cancer in Serbia and in Europe. *Acta Facultatis Medicae Naissensis.* 2018;35:5-16.
45. Clinical Practice Guidelines in Oncology V.2. National Comprehensive Cancer Network. 2013.
46. WHO. Comprehensive Cervical Cancer Control. Jenewa. 2006.
47. Crowder S, Lee C, Santoso JT. Cervical Cancer. Dalam: Santoso JT, Coleman RL (eds). *Handbook of Gynaecology Oncology.* 1<sup>st</sup> Ed. New York: Mc Graw Hill. 2001:25-32.
48. Nuranna L. Penanggulangan Kanker Serviks Yang Sahih dan Andal Dengan Model Proaktif-VO (Proaktif, Koordinatif Dengan Skrining IVA dan Terapi Krio). [Disertasi]. Program Pasca Sarjana FKUI. Jakarta. 2005.
49. Benedet J, Odicino F, Maisonneuve P, et al. Carcinoma of The Cervix Uteri. Annual Report. The Results of Treatment in Gynecological Cancer. *Epidemiol Biostat.* 1998.
50. Johnson T. Cervical Cancer. WebMD. 2020.
51. Senol T, Polat M, Ozkaya E, Karateke A. Comparison of Two Step LEEP and Cold Conisation For Cervical Intraepithelial Lesions to Decrease Positive Surgical Margins. *Asian Pac J Cancer Prev.* 2016;17(7):3317-20.
52. Zhu L, Li L, Li Y, Wang J, Wang Q. Chinese herbal medicine as an adjunctive therapy for breast cancer: A systematic review and meta-analysis. *Evidence-based Complement Altern Med.* 2016;2016
53. Wen-jing R, Mao-de LAI, Jian-guang Z. Anticancer effects of Chinese herbal medicine, science or myth?. 2006;7(12):1006-14.
54. Ma'at, Suprpto. *Teknik Dasar Kultur Sel.* University Press. Surabaya: Airlangga. 2011.
55. Syahidah HN, Hadisaputri YE. Media yang digunakan pada kultur sel. *Farmaka.* 2016;14:27-36.
56. Rahbari R, Sheahan T, Modes V, Collier P, Macfarlane C, Badge RM. A novel L1 retrotransposon marker for HeLa cell line identification. *BioTechniques.* 2009;46(4):277-284.
57. Batts DW (2010-05-10). Cancer cells killed Henrietta Lacks – then made her immortal. *The Virginian-Pilot.* 2010;1:12-14.

58. Puck TT, Marcus PI. A rapid method for viable cell titration and clone production with HeLa cells in tissue culture: The use of X-irradiated cells to supply conditioning factors. *Proceedings of the National Academy of Sciences of the United States of America*. 1955;41(7):432–437.
59. Smith V. *Wonder Woman: The Life, Death, and Life After Death of Henrietta Lacks, Unwitting Heroine of Modern Medical Science*. Baltimore City Paper. 2002.
60. Ivanković M, Cukusić A, Gotić I, Skrobot N, Matijasić M, Polancec D, Rubelj I. Telomerase activity in HeLa cervical carcinoma cell line proliferation. *Biogerontology*. 2007;8(2):163–72.
61. Vartiainen S. *Caenorhabditis elegans*. *Encycl Mov Disord*. Published online 2010:171-73.
62. Reece JB, Urry M, Cain, SA, Wasserman PV, Minorsky, Jackson. *The Cell Cycle*. Campbell Biology 10th ed. San Francisco, CA: Pearson. 2011:232-50.
63. Kumar V, Cotran RS, Robbins SL. Buku ajar patologi robbins/ Vinay Kumar; alih bahasa, Ening krisnuhoni; editor edisi Bahasa Indonesia, I Made Nasar, Santoso Cornain. Jakarta : Penerbit Buku Kedokteran EGC. 2013:16-20.
64. Wong R. Apoptosis in cancer: From pathogenesis to treatment. *J Exp Clin Canc Res* 2011;30(87):1-14.
65. Thompson, Barry J. Developmental control of cell growth and division in *Drosophila*. *Current Opinion in Cell Biology*. 2010;22(6):788–794.
66. Saucedo L. Why size matters: altering cell size. *Current Opinion in Genetics & Development*. 2002;12(5):565–571.
67. Vicente-Manzanares M, and Horwitz AR. Cell migration: an overview. *Methods Mol. Biol.* 2011;769:1-24.
68. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, and Horwitz AR. Cell migration: integrating signals from front to back. *Science*. 2003;302(5651):1704-9.
69. Lee YC, Lin HH, Hsu CH, Wang CJ, Chiang TA. and Chen JH. Inhibitory effects of andrographolide on migration and invasion in human non-small cell lung cancer A549 cells via downregulation of PI3K/Akt signaling pathway, *Eur. J. Pharmacol.* 2010;632(1–3):23–32.
70. Yamaguchi H dan Condeelis J. Regulation of the Actin Cytoskeleton In Cancer Cell Migration and Invasion, *Biochimica et Biophysica Acta*. 2007;1773:642 – 652.
71. Slack JMW. *Essential Developmental Biology*. Wiley-Blackwell, Oxford. 2013.
72. Kumar S, Bentley PJ. *Cell Differentiation. An introduction to computational development*. 2003.

73. Hutomo S, Susilowati H, Suryanto YI, Kurniawan C. Perubahan morfologi sel HeLa setelah paparan ekstrak etanolik *Curcuma longa*. Fakultas Kedokteran Gigi, Universitas Gadjah Mada, Yogyakarta. 2016.
74. Steven AA, L Randers, and G Rao. Comparison of trypan blue dye exclusion and fluorometric assays for mammalian cell viability determinations. *Biotechnol.* 1993;9(6):671-674.
75. Liang CC, Park AY, Guan JL. In vitro assay : a convenient and inexpensive method for analysis of cell migration in vitro [Abstrak]. *Natprotoc.* 2007;2(2):329-33.
76. CRCC. Pengamatan Migrasi dengan Scratch Wound Healing Assay. Cancer Chemoprevention Research Center, Fakultas Farmasi UGM, Yogyakarta. 2015.
77. Strober W. Trypan blue exclusion test of cell viability. *Curr Protoc Immunol.* 2001;21(1):1-2.
78. Bio-Rad. TC10 Automated Cell Counter. Bio-Rad Laboratories, Inc. <https://www.biorad.com/webroot/web/pdf/lsr/literature/Bulletin%205929.pdf>
79. Arisanty D. In Vitro Cytotoxic Study and Detection of Apoptosis on Breast Cancer Cell lines MDA-MB 231 after Exposed to *Azadirachta Indica* A. Juss (neem) Extract. *J Kesehat Andalas.* 2013;2(2):80.
80. Rachmawati E. Efek Ekstrak Etanolik Daun Sirsak pada Proliferasi dan Apoptosis Sel HeLa yang Dimediasi oleh P53. *J Kedokt Brawijaya.* 2012;27(1).
81. Badarinath A, Rao K, Chetty CS, Ramkanth S, Rajan T, Gnanaprakash K. A Review on In-vitro Antioxidant Methods : Comparisons, Correlations, and Considerations. *International Journal of PharmTech Research.* 2010: 1276-1285.
82. Cory G. Scratch-wound Assay. *Methods Mol Biol.* 2011;769:25-30.
83. Ilina O, Friedl P. Mechanisms of Collective Cell Migration at a Glance. *J Cell Sci* 2009; 122:3203-8.
84. Fujisawa T, Rubin B, Suzuki A, Patel PS, Gahl WA, Joshi BH, Puri RK. Cysteamine Suppresses Invasion, Metastasis and Prolongs Survival by Inhibiting Matrix Metalloproteinases in a Mouse Model of Human Pancreatic Cancer. *PLoS One.* 2012; 7:e34437.
85. Kim JH, Serra-Picamal X, Tambe DT, Zhou EH, Park CY, Sadati M, Park J-A, Krishnan R, Gweon B, Millet E, et al. Propulsion and Navigation Within the Advancing Monolayer Sheet. *Nat Mater.* 2013; 12:856-63